埃索美拉唑治疗胃食管反流性疾病效果好吗？

The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's esomeprazole (Nexium) for the short-term treatment of children with gastroesophageal reflux disease (GERD) associated with erosive esophagitis. Is esomeprazole effective in treating gastroesophageal reflux disease?

The product is the first proton pump inhibitor drug approved for use in infants younger than one year old. The approval is based on the results of a randomized, open-label, multinational study that evaluated the pharmacokinetics of repeated intravenous (once-daily) administration of esomeprazole. According to the latest drug labeling, the drug is well tolerated in pediatric patients aged 1 month to 17 years old (inclusive).

Esomeprazole sodium for injection is only suitable for use in children over one month old who are difficult or unsuitable for oral treatment. According to the drug label, intravenous therapy with esomeprazole sodium for injection should be discontinued and oral therapy should be continued whenever oral therapy is possible or appropriate. The label also notes that the drug's safety has not been proven when used for more than 10 days.

Clinical trial results show that esomeprazole (Nexium) is effective in treating pediatric patients. GERD is characterized by abnormal sphincter closure that causes gastric acid to reflux into the esophagus. Children and adults suffering from the disease often experience heartburn, regurgitation, and stomach discomfort. If left untreated, acid reflux can lead to potentially damaging inflammation of the esophagus, also known as erosive esophagitis.

Esomeprazole (Nexium) has been marketed in many countries. In 2000, the oral formulation of esomeprazole (Nexium) was first launched in Sweden. In 2001, it was approved by the FDA to be marketed in the United States under the trade name Nexium. In 2003, esomeprazole sodium for injection developed by AstraZeneca was first launched in Sweden and was approved for marketing in the United States in 2005. For more information about esomeprazole, please consult Medical Companion Travel.